en · de · es · pt
assay-notes.peptides9002.com › News › Tesamorelin Identity And Structure — Evidence Review

Tesamorelin Identity And Structure — Evidence Review

By Editorial Desk · published 2025-10-28 · last reviewed 2025-11-15 · News

hexenoyl group comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Last reviewed on 2025-11-15. Where a claim depends on a specific study, the study is described rather than over-claimed.

Tesamorelin Identity And Structure

Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.

The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.

特沙莫瑞林分析与储存要点

稳定性研究通常考察温度、光照、湿度和 pH 对肽链的影响。冻干粉在低温避光条件下较为稳定,复溶后则需控制保存时间并避免反复冻融。肽类可能发生氧化、脱酰胺、水解和聚集,这些变化会改变色谱纯度。强制降解实验用于识别主要降解途径并验证分析方法的专属性。

质量控制项目一般包括外观、身份、纯度、含量、有关物质、水分和微生物限度。身份确认可通过肽图谱、氨基酸分析和质谱完成,纯度则用面积归一化法计算。研究级材料与药品级材料的要求不同,前者常缺少完整药典验证。不同批次间杂质谱是否影响活性,仍是一个需要具体数据回答的问题。

Tesamorelin at a glance

PropertyValueNotes
Chemical classSynthetic peptideGHRH analog family
Residue count44 amino acidsMatches human GHRH(1-44) backbone
N-terminal grouptrans-3-hexenoylMain structural difference from native hormone
AppearanceWhite to off-white powderLyophilized solid form
Solubility classFreely soluble in waterPeptide character; less soluble in organic solvents

Identity and Development Background

Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Related pages on this site

Analytical Methods and Storage Handling

Stability testing examines how the molecule changes under controlled stress. Thermal stress, light exposure, and extremes of pH are applied separately so that each degradation route can be attributed to a specific cause. The main observed changes are oxidation, deamidation, and aggregation into dimers or higher-order species. Accelerated studies at elevated temperature are used to estimate behavior over longer periods, though such extrapolation carries uncertainty. For a lyophilized powder, residual moisture and the choice of bulking agent strongly influence how quickly these changes appear.

Practical handling centers on limiting moisture, oxygen, and temperature excursions. Lyophilized material is generally held at or below minus twenty degrees Celsius, protected from light and kept sealed until use. Once reconstituted, solutions are typically kept cold and used within a short window because hydrolysis and microbial growth both accelerate in liquid form. Repeated freeze-thaw cycles are avoided, since they promote aggregation. Vial contents should be inspected for particulates and clarity before analysis, and working aliquots are prepared to reduce the number of times the stock is opened.

Supporting material

=== Vagina, uterus, ovaries === Perineal skin keratinizes due to effect of estrogen increasing its resistance to infection. The mucosal surface of the vagina also changes in response to increasing levels of estrogen, becoming thicker and duller pink in color (in contrast to the brighter red of the prepubertal vaginal mucosa). Mucosa changes into a multilayered structure with superficial layer of squamous cells. Estrogen increases glycogen content in vaginal epithelium, which in future plays important part in maintaining vaginal pH. Whitish secretions (physiologic leukorrhea) are a normal effect of estrogen as well. In the two years following thelarche, the uterus, ovaries, and the follicles in the ovaries increase in size.

In the war against the Marcomanni in 167, the town was hard pressed; its fortifications had fallen into disrepair during the long peace. Nevertheless, when in 168 Marcus Aurelius made Aquileia the principal fortress of the empire against the barbarians of the North and East, it rose to the pinnacle of its greatness and soon had a population of 100,000. Septimius Severus visited in 193. In 238, when the town took the side of the Senate against the emperor Maximinus Thrax, the fortifications were hastily restored, and proved of sufficient strength to resist for several months, until Maximinus himself was assassinated.

A study conducted by researchers at the University of Alabama examined the adhesive properties of fibrin tissue adhesives. The tests found that fibrin adhesives even at its intended medical concentration (29 mg/mL at the wound site) had shear strength of only 17.6 kiloPascals. Furthermore, another study performed at the University of California determined that the modulus (the stress/strain) of fibrin adhesives was on average 53.56 kPA. To seal together tissues the human body uses collagen and elastin to obtain superior shear strength. Type I collagen which includes collagen strands bundled into strong fibrils has a unique tri-helical structure which increases the proteins structural integrity. In fact, a study performed by the Department of Medicine in University College London experimentally determined that pure type I collagen has a modulus of 5 GPa to 11.5 GPa. Therefore, pure type I collagen has nearly one million times greater structural integrity than fibrin. Collagen is therefore much harder to deform than fibrin, and collagen fibers create much stronger bonds between tissues than strands of fibrin polymer.

During maximum intensity exercise, muscle glycogen can supply 40 mmol glucose/kg wet weight/minute, whereas blood glucose can supply 4 – 5 mmol. Due to its high supply rate and quick ATP synthesis, during high-intensity aerobic activity (such as brisk walking, jogging, or running), the higher the exercise intensity, the more the muscle cell produces ATP from muscle glycogen. This reliance on muscle glycogen is not only to provide the muscle with enough ATP during high-intensity exercise, but also to maintain blood glucose homeostasis (that is, to not become hypoglycaemic by the muscles needing to extract far more glucose from the blood than the liver can provide). A deficit of muscle glycogen leads to muscle fatigue known as "hitting the wall" or "the bonk" (see below under glycogen depletion).

Sources: en.wikipedia.org

Supporting material

== Treatment == There are many causes of necrosis, and as such treatment is based upon how the necrosis came about. Treatment of necrosis typically involves two distinct processes: Usually, the underlying cause of the necrosis must be treated before the dead tissue itself can be dealt with.

=== Young adult and teenage users === Worldwide, increasing numbers of young people are vaping. With access to e-cigarettes, young people's tobacco use has dropped by about 75%. Most young e-cigarette users have never smoked, but there is a substantial minority who both vape and smoke. Many young people who would not smoke are vaping. Young people who smoke tobacco or marijuana, or who drink alcohol, are much more likely to vape. Among young people who have tried vaping, most used a flavored product the first time. Vaping correlates with smoking among young people, even in those who would otherwise be unlikely to smoke. In the U.S., among young people, e-cigarette use increased rapidly in the late 2010s, peaked in 2019, and had fallen substantially by 2024 (7.8% in high school students and 3.5% in middle school students). During that period, the FDA also expanded enforcement activity against unauthorized e-cigarette products. Despite these declines, e-cigarettes remained the most commonly used tobacco product among US youth for the 11th consecutive year in 2024, while cigarette smoking reached historically low levels (1.4% current use). Compared to e-cigarettes, conventional cigarette use had fallen to 1.7% among high school students and 1.1% among middle school students, the lowest prevalence recorded by the survey, according to the 2024 NYTS. Among young people who used e-cigarettes in 2024, 26.3% reported daily use and 87.6% used flavored products, with fruit flavors being the most common.

=== Controlled-release formulations === Controlled or modified-release formulations are designed to deliver medications at a steady rate over time, helping maintain consistent drug levels in the bloodstream. This steady release reduced how often patients need to take their medication and minimizes the ups and downs in drug concentration that can cause side effects or lower effectiveness. These systems often take the form of matrix tablets, osmotic pumps, and reservoir-type devices, all of which use physical or chemical barriers to regulate how the drug is released. This approach is especially useful for chronic conditions such as high blood pressure, diabetes, or chronic pain, where maintaining stable therapeutic levels is key to keeping symptoms under control. The concept of controlled-release medication dates back to the 1950s, when Dexedrine became the first such formulation on the market. This era saw the introduction of transdermal patches, which deliver drugs slowly through the skin. As technology progressed, new formulations were developed to match the specific properties of different drugs. Examples include long-acting depot injections for medication like antipsychotics and hormone therapies, which remain effective for weeks or even months after a single dose. Since the late 1990s, research has increasingly turned to nanotechnology as a way to improve controlled-released drug delivery.

=== Civil and criminal proceedings === In March 2018, the US Securities and Exchange Commission filed civil fraud charges against Theranos, its CEO Holmes and former president Ramesh "Sunny" Balwani, claiming they had engaged in an "elaborate, years-long fraud" wherein they "deceived investors into believing that its key product – a portable blood analyzer – could conduct comprehensive blood tests from finger drops of blood". Holmes reached a settlement with the SEC which required her to pay $500,000, forfeit 19 million shares of company stock, and be barred from having a leadership position in any public company for ten years. Balwani did not settle with the SEC. On June 15, 2018, Holmes and Balwani were indicted on multiple counts of wire fraud and conspiracy to commit wire fraud. According to the indictment, investors, doctors and patients were defrauded. It is alleged that the defendants were aware of the unreliability and inaccuracy of their products, but concealed that information. The case, United States v. Elizabeth A. Holmes, et al., was assigned to Lucy H. Koh, United States district judge of the United States District Court for the Northern District of California. The jury selection for the trial was to begin on July 28, 2020, and the trial was to have commenced in August 2020; however, the COVID-19 pandemic led to a proposed October date, before the trial for Holmes was rescheduled to begin on August 31, 2021, with Balwani's trial pushed back further to 2022.

These strongly electrophilic NAIs allow for reactions with a wide range of nitrogen nucleophiles, including hindered and electron-deficient amines. An added benefit of the use of NMI as the base, due to its low pKa(H2O) of 7, is that the epimerization of labile stereogenic centers is minimized. The reaction by-products have high water solubility, facilitating reaction workup and isolation.

Sources: en.wikipedia.org

Frequently asked questions

Is tesamorelin the same as growth hormone?

No. It is a peptide that acts upstream of growth hormone release, while growth hormone is the hormone itself. The two differ in size, in receptor, and in how the body clears them.

What does the trans-3-hexenoyl group do?

It blocks the amino-terminal degradation step that limits native GHRH. The addition extends how long the peptide survives in plasma without removing its ability to activate the receptor.

How long is the peptide chain?

The chain contains 44 amino acid residues. It matches the human GHRH(1-44) sequence apart from the amino-terminal modification.

哪些分析方法常用于确认特沙莫瑞林?

反相高效液相色谱用于分离和纯度评估,质谱用于分子量确认。肽图谱或串联质谱可进一步验证序列。具体方法需根据样品基质和监管要求选择。

Network